A spectrum of skin reactions caused by the tyrosine kinase inhibitor imatinib mesylate (STI 571, Glivec®) [4]

British Journal of Haematology

Volumn 120, Issue 5, 2003, Pages 911-913

  Drummond, A ^a   Micallef Eynaud, P ^b   Douglas, W S ^a   Murphy, J A ^c   Hay, I ^d   Holyoake, T L ^e   Drummond, M W ^e  

^a Monklands Hospital   (United Kingdom)

^b CROSSHOUSE HOSPITAL   (United Kingdom)

^c Monklands University Hospital   (United Kingdom)

^d ROYAL ALEXANDRA HOSPITAL   (United Kingdom)

^e UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

Chronic myeloid leukaemia; Erythema nodosum; Imatinib mesylate; Skin rash; Vasculitis

Indexed keywords

IMATINIB; PROTEIN TYROSINE KINASE INHIBITOR;

CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; DIARRHEA; DRUG WITHDRAWAL; EDEMA; ERYTHEMA NODOSUM; FEMALE; GRAFT VERSUS HOST REACTION; HUMAN; LETTER; MAJOR CLINICAL STUDY; MALE; MYALGIA; NAUSEA; PRIORITY JOURNAL; RASH; SKIN MANIFESTATION; SKIN TOXICITY; SMALL VESSEL VASCULITIS;

ANTINEOPLASTIC AGENTS; COHORT STUDIES; DRUG ERUPTIONS; ENZYME INHIBITORS; FOLLOW-UP STUDIES; HUMANS; LEUKEMIA, MYELOID, CHRONIC-PHASE; PIPERAZINES; PROSPECTIVE STUDIES; PYRIMIDINES;

EID: 0344716604     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2141.2003.04151_4.x     Document Type: Letter

References (6)

1. Brouard, M. & Saurat, J.-H. (2001) Cutaneous reactions to STI571. New England Journal of Medicine, 345, 618-619.
2. Druker, B.J., Talpaz, M., Resta, D.J., Peng, B., Buchdunger, E., Ford, J.M., Lydon, N.B., Kantarjian, H., Capdeville, R., Ohno-Jones, S. & Sawyers, C.L. (2001) Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. New England Journal of Medicine, 344, 1031-1037.
3. Eming, S.A., Peters, T., Hartmann, K., Scharfetter-Kochanek, K. & Mahrle, G. (2001) Lichenoid chronic graft-versus-host-disease-like acrodermatitis induced by hydroxyurea. Journal of the American Academy of Dermatology, 45, 321-323.
4. Feng, L., Drummond, M., Byrne, J., Shepherd, P., Apperley, J., Clarke, R., Craddock, C., O'Brien, S., Cervantes, F., Lennard, A., Holyoake, T., Goldman, J.M. & Kaeda, J.S. (2002) Molecular remission following treatment with STI571 for chronic myeloid leukaemia: a report from the UK STI571 Study Group. British Journal of Haematology, 117, Abstract 10.
5. Hsiao, L., Chung, H., Lin, J., Chiou, T., Liu, J., Fan, F.S., Wang, W., Yen, C. & Chen, P. (2002) Stevens-Johnson syndrome after treatment with STI571: a case report. British Journal of Haematology, 117, 620-622.
6. Kantarjian, H., Sawyers, C., Hochhaus, A., Guilhot, F., Schiffer, C., Gambacorti-Passerini, C., Niederwieser, D., Resta, D., Capdeville, R., Zoellner, U., Talpaz, M., Druker, B. and the International STI571 CML Study Group (2002) Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. New England Journal of Medicine, 346, 645-652.